Abbott Laboratories (XSWX:ABT) LT-Debt-to-Total-Asset: 0.27 (As of Mar. 2026)

What is Abbott Laboratories LT-Debt-to-Total-Asset?

Abbott Laboratories XSWX:ABT +0.66% 80 LT-Debt-to-Total-Asset is 0.27 as of Mar. 2026. GuruFocus rates XSWX:ABT with a GF Score™ of 80/100 and a GF Value™ of CHF104.56.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Abbott Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.27.

Abbott Laboratories's long-term debt to total assets ratio increased from Mar. 2025 (0.16) to Mar. 2026 (0.27). It may suggest that Abbott Laboratories is progressively becoming more dependent on debt to grow their business.

Abbott Laboratories (XSWX:ABT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Abbott Laboratories LT-Debt-to-Total-Asset Related Terms

Abbott Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories LT-Debt-to-Total-Asset Chart

Abbott Laboratories Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.24

0.21

0.20

0.17

0.13

Abbott Laboratories Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.15	0.14	0.13	0.27

80GF Score

Abbott Laboratories XSWX:ABT

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Abbott Laboratories LT-Debt-to-Total-Asset Calculation

Abbott Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	8628.036	/	69101.59
	=	0.12

Abbott Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	23333.997	/	86940.752
	=	0.27

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.27 mean?

Abbott Laboratories (XSWX:ABT) has a LT-Debt-to-Total-Asset of 0.27 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Abbott Laboratories and its competitors.

Is Abbott Laboratories' LT-Debt-to-Total-Asset too high?

Abbott Laboratories' current LT-Debt-to-Total-Asset is 0.27. Overall, Abbott Laboratories has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.

How does Abbott Laboratories' LT-Debt-to-Total-Asset compare to SYK and MDT?

Abbott Laboratories' LT-Debt-to-Total-Asset of 0.27 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current LT-Debt-to-Total-Asset is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Abbott Laboratories stock overvalued right now?

Abbott Laboratories (XSWX:ABT) has a current LT-Debt-to-Total-Asset of 0.27. The stock's GF Value™ is CHF104.56, compared to a current price of CHF76.00 — trading 27.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.27. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current LT-Debt-to-Total-Asset is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of CHF76.00 is trading 27.3% below its estimated GF Value™ of CHF104.56.

Key valuation signals for XSWX:ABT:

LT-Debt-to-Total-Asset: 0.27
GF Value™: CHF104.56 vs. price of CHF76.00 (27.3% below fair value)
GF Score™: 80/100

No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies SYK MDT BSX EW DXCM GEHC STE ZBH PEN GMED XTER:SHL SZSE:300760 XAMS:PHIA XSWX:SOON SHSE:688271 LSE:SN.TSE:7733 PODD MASI BRKR

Other Exchanges ABT:USA ABT:Peru ABT:Mexico 1ABT:Italy 0Q15:UK ABL:Germany ABT:Chile ABT:Canada ABTT34:Brazil ABL:Bulgaria ABT:Austria ABT:Argentina

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website https://www.abbott.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

80GF Score

Get the complete analysis for XSWX:ABT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF76.00

Price

CHF104.56

GF Value

View XSWX:ABT Analysis

See LT-Debt-to-Total-Asset data for all stocks →